Search

Displaying results 1881 - 1890 of 7604 in total
  1. Drug

    Insulin beef

    go.drugbank.com/drugs/DB09456
    Approved

    Insulin beef has been discontinued in the US and Canada since 2017.[L10827]

    Categories: Insulins and Analogues for Injection, Fast-Acting
  2. Drug

    Relugolix

    go.drugbank.com/drugs/DB11853
    ApprovedInvestigational

    [A225926] In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and [norethindrone] under the market name Myfembree for the first once-daily treatment for the management … Orgovyx, for the treatment of advanced prostate cancer.

  3. Drug

    Trilaciclib

    go.drugbank.com/drugs/DB15442
    ApprovedInvestigational

    chemotherapy for extensive stage small cell lung cancer. … [L31828] CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.[A229323] Trilaciclib was first described in the literature in 2016.

    Categories: Detoxifying Agents for Antineoplastic Treatment, MATE 2-K Inhibitors
  4. Drug

    Relacorilant

    go.drugbank.com/drugs/DB14976
    ApprovedInvestigational

    [L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089]

  5. Drug

    Flurbiprofen

    go.drugbank.com/drugs/DB00712
    ApprovedInvestigational

    Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. … Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis.

    Categories: Topical Products for Joint and Muscular Pain, Antiinflammatory Preparations, Non-Steroids for Topical Use
  6. Drug

    Streptococcus pneumoniae type 18c capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10335
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: PREVENAR 13 SUSPENSION FOR INJECTION, Prevenar 13 Suspension For Injection
  7. Drug

    Zalcitabine

    go.drugbank.com/drugs/DB00943
    ApprovedWithdrawn

    This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseProducts: ZALCITABINA MK 0.75 MG
  8. Drug

    NKG2D-ACE2 CAR-NK Cell

    go.drugbank.com/drugs/DB15727
    Investigational

    The transmembrane NKG2D and intracellular 2B4 domains are required for optimal NK signalling and subsequent cell-mediated cytotoxicity. … The IL-15 superagonist increases the activity of NK cells and improves their target cytotoxicity. The GM-CSF acts as a neutralizer for the CAR-T cell-mediated cytokine release and neurotoxicity.

    Synonyms: ACE2 CAR-NK Cell, NKG2D CAR-NK Cell
  9. Drug

    Fosnetupitant

    go.drugbank.com/drugs/DB14019
    ApprovedInvestigational

    Fosnetupitant is the pro-drug form of netupitant [FDA label]. … the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for

  10. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    [A214280, A214295] On January 16, 2024, inebilizumab also received Health Canada approval for the same indication. … [L49861] In April 2025, inebilizumab was additionally approved by the FDA for immunoglobulin G4-related disease (IgG4-RD).[L52705,L14315] It is the first and only FDA-approved treatment for IgG4-RD.